Our large practice urology group has partnered with theralogix, a vitamin company to offer patients products that have been shown in study to help with various conditions.
Prosteon is a bone health supplement for men undergoing Androgen Deprivation Therapy (hormone therapy), or for anyone looking to support their bone health.
It can be ordered through:
The U.S. Food and Drug Administration approved enzalutamide for the treatment of patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). At the prespecified interim analysis, a statistically significant improvement in overall survival was demonstrated for patients
Source: U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
I have been using enzalutamide in my patients who have metastatic disease proven by imaging or pathology and have progressed where hormonal therapy isn’t enough to keep the PSA near 0.
Prostate cancer patients starting treatment with androgen deprivation therapy (ADT) who were already taking cholesterol-lowering statins had a 10-month prolonged time to cancer progression compared with patients who were not on statins, according to the results of a new study published in JAMA Oncology. – See more at: Statins Benefit ADT-Treated Prostate Cancer Patients | Cancer Network.
This study reported men starting on hormonal therapy who already were taking statin therapy for high cholesterol had better results than men not taking statins.
There have been many studies that show that taking statins help reduce the risk of prostate cancer recurrence.
I encourage patients that have borderline high cholesterol to speak to their primary care doctors about starting on statin therapy.
Men with locally advanced prostate cancer (PCa) have a better chance of survival when they add radiation therapy (RT) to their hormone therapy, according to research presented at the 52nd annual meeting of the American Society for Radiation Oncology.
via Added Radiation to ADT May Improve Survival – Renal and Urology News.
This is another study that finds a survival advantage in adding radiation therapy to hormonal therapy in advanced prostate cancer. Traditionally, urologists treated these patients with hormonal therapy only since radiation was not curative.
Newer studies are showing that external beam radiation added to hormonal therapy helps people live longer. I think this is because radiation therapy is safer than it was in the past and treating the primary tumor may help prevent future metastases.
Source Medwire News
Adding local radiotherapy to endocrine treatment halves the 10-year prostate cancer-specific mortality in patients with locally advanced or high-risk local prostate cancer compared with endocrine treatment alone, researchers report.
“In the light of these data, endocrine treatment plus radiotherapy should be the new standard,” Anders Widmark (Umeå University, Sweden) and team write in The Lancet.
This study looked at 875 patients with locally advanced prostate cancer (T3; 78%; PSA<70; N0; M0) without evidence of distant spread. These men were from multiple centers in Norway, Sweden, and Denmark. In this set of patients, adding radiation helped men live longer compared to hormonal therapy alone.
The only difference in my practice, and in many centers in the US is that we sometimes perform surgery for these patients as well. The other difference is that these patients were given continuous endocrine treatment using flutamide, which is not as effective as other hormonal therapy regimens that we usually use (gonadotropin-releasing hormone (GnRH) agonists).